Introduction and hypothesis The objective was to compare the outcomes of the ACT® device with those of the artificial urinary sphincter (AUS) AMS 800 in the treatment of stress urinary incontinence (SUI) due to sphincter deficiency in women. Methods All the women who underwent surgical treatment for SUI due to intrinsic sphincter deficiency from 2007 to 2017 were included in a single-center retrospective study. The primary endpoint was the functional outcome. Perioperative functional parameters of the two groups were compared. Results Twenty-five patients underwent an ACT® implantation and 36 an AUS implantation. Patients in the AUS group were younger (62.9 vs 70.4 years; p = 0.03) with less comorbidity (ASA Score = 3 in 12.1% vs 33.3%; p = 0.005). Operative time and hospital stay were shorter in the ACT® group (45.7 vs 206.1 min; p < 0.001; 1.7 vs 7 days; p < 0.001 respectively). There was a higher rate of intraoperative complications in the AUS group (47% vs 8%; p < 0.001) but the rates of postoperative complications were similar between both groups. The ACT® was associated with an increased risk of urinary retention (20% vs 2.8%; p = 0.04). Results were in favor of AUS for: decrease in USP stress incontinence subscore (−7.6 vs −3.2; p < 0.001), number of pads per 24 h (− 4.6 vs −2.3; p = 0.002), PGII scale (PGII = 1: 61.1% vs 12%; p < 0.001), and cure rate (71.4% vs 21.7%; p < 0.001). Conclusions In the present series, keeping in mind the significantly different baseline characteristics, AUS implantation was associated with better functional outcomes than the ACT® in female patients with SUI due to intrinsic sphincter deficiency, but with a higher intraoperative complications rate, longer operative time, and a longer stay.
Introduction
Stress urinary incontinence (SUI) due to intrinsic sphincter deficiency is usually defined as the combination of a low urethral closure pressure, loss of urethral mobility, and a negative Marshall/Bonney test (urine leakage on straining or coughing not corrected by urethral support) [1, 2] . In daily practice, this condition is usually seen in two different populations: female patients in whom previous anti-incontinence surgical procedures (recurrent or persistent urinary incontinence after midurethral sling, Burch colposuspension, etc.) failed [3] or patients with neurogenic SUI (usually due to spinal cord injury or spina bifida) [4] . The management of these women remains highly controversial, fascial slings and bulking agents being the most commonly used treatment option in North America [5] , whereas in several European countries, notably in France, external compression devices, such as the Adjustable Continence Therapy (ACT®; Uromedica, Plymouth, MN, USA) or the artificial urinary sphincter (AUS) AMS 800 (American Medical Systems, Minnetonka, MN, USA), are usually favored. Although several series have assessed the outcomes of various surgical treatments for intrinsic sphincter deficiency [1] , studies comparing two treatment options are lacking. The aim of this study was to compare the outcomes of the ACT® device with that of the artificial urinary sphincter AMS 800 in the treatment of SUI due to intrinsic sphincter deficiency in women.
Materials and methods

Study design
All 61 women who underwent a surgical treatment for SUI due to intrinsic sphincter deficiency from 2007 to 2017 were included in a single-center retrospective study. Intrinsic sphincter deficiency was defined as the combination of a low urethral closure pressure (<40 cm H 2 O), loss of urethral mobility, and a negative Marshall/Bonney test (urine leakage on straining or coughing not corrected by urethral support). The artificial urinary sphincter AMS 800 was considered the standard treatment in these patients during the study period. The ACT® periurethral balloons became available in our center in 2011 and were used only in the following cases: moderate incontinence (subjectively defined as pad test <200 g/ 24 h), patients aged over 80 years, and/or morbidly obese, and/or lacking manual dexterity limiting the ability to operate the sphincter pump, etc.), and/or with history of previous pelvic radiation therapy, and/or patients who refused the implantation of an artificial urinary sphincter. From 2007 to 2011, all patients were offered AUS with no alternatives and from 2011 to 2017 patients with the aforementioned comorbidities and those with moderate incontinence were offered peri-urethral balloons and the other patients were offered an AUS (but some refused and preferred to receive peri-urethral balloons). In accordance with national guidelines [1] , no other surgical treatment (e.g., fascial sling, bulking agents) was used to treat intrinsic sphincter deficiency during the study period. Hence, the inclusion criteria were: all female patients who underwent a surgical treatment for SUI due to intrinsic sphincter deficiency from 2007 to 2017. The study was approved by the local ethics committee and was conducted following the principles of the Declaration of Helsinki. Consent from all study participants was obtained. The study was not supported by the industry. The primary endpoint was the functional outcome categorized as: cured (complete continence, i.e., no pads used), improved (decrease in the number of pads per day or in urine leakage assessed through the pad test) or failure (no decrease in the number of pads per day or urine leakage assessed through the pad test).
Adjustable continence therapy: device and surgical technique
All patients had a negative preoperative urine culture and received 2 g of cephalosporin group 2 at the beginning of the procedure as antibiotic prophylaxis. Patients with a positive preoperative urine culture (≥10 3 CFU/mL) received antibiotic treatment according to the sensitivity of the bacteria isolated from their urine culture for a minimum period of 2 days before the implantation.
The ACT® kit contains two silicone elastomer balloons connected to a titanium port, a syringe and a puncture needle used to inflate the device through the titanium port. Balloons are available in four lengths from 6 to 9 cm, which is determined using the trocar. The latter is one of the dedicated tools with a tipped stylet and a blunt-tipped stylet.
The surgical procedure was performed as previously described by others [1, [6] [7] [8] . The balloons were placed at each side of the bladder neck using the trocar, which was inserted using an incision in each labia majora, and the devices were pushed laterally to the urethra to their correct position on each side of the bladder neck, slightly posterior (at 5 o'clock and 7 o'clock), which was controlled by fluoroscopy and flexible cystoscopy. The balloons were filled with 0.6 ml of an aqueous radiopaque solution through the titanium port, which was placed subcutaneously in the labia majora. The trocar was removed after inflation of the device to avoid moving the device during removal.
A urethral catheter was introduced for up to 12 h and removed before the patient was discharged. The procedure was performed as outpatient surgery when deemed possible.
The ACT implantations were performed by two surgeons with no previous experience of this surgery before the study period. Inflations of 0.6 ml were performed once a month from 1 month postoperatively in outpatient clinics without any anesthesia by injecting into the titanium ports, until a satisfactory improvement was observed and up to a maximum of 7 ml per balloon.
Artificial urinary sphincter: device and surgical technique
The antibiotics policy used was similar to that for ACT implantations (see above). The device used was the AMS 800 in all cases. The surgical techniques used were those previously described and followed the same principles regardless of the approach [9] . Briefly, the Retzius space was dissected until the bladder neck and the endopelvic fascia was opened on both sides of the urethra. The bladder neck was then dissected from the vagina below the periurethral fascia just below the level of the catheter balloon. The surgeon introduced two fingers of his left hand into the vagina to help the dissection. At the end of the dissection, the bladder was filled with saline stained with methylene blue to verify the integrity of the bladder neck. The bladder neck circumference was measured using a measuring tape. The cuff was then positioned around the bladder neck. The pump was implanted into one of the labia majora and the balloon into the prevesical space. An open approach was used between 2007 and 2012 with a few laparoscopic cases over this period. From 2012 to 2017, all implantations were performed via a robot-assisted approach. A single surgeon (AM) highly experienced in functional urology performed all open and laparoscopic cases. He was then involved as the assistant surgeon in the surgical field for the robotic implantations, while two consecutive surgeons were performing the dissection at the console: a first surgeon highly-experienced in robotic surgery (SV; > 600 robotassisted radical prostatectomy at the beginning of the present study) performed the first ten cases and a second surgeon (BP, a young fellow who had performed only 20 robotic procedures before his first robotic AUS implantation) performed the subsequent cases.
The AUS were deactivated at the time of implantation and the urethral catheter was removed 2 days after surgery; bladder ultrasound was carried out to confirm adequate bladder voiding after catheter removal. Patients returned 6 weeks later to activate and learn how to use the sphincter.
Pre-and postoperative assessments
All patients underwent a complete work-up before surgery including: urodynamics, urethrocystoscopy, 3-day bladder diary, and a pad test. The preoperative assessment also comprised a clinical interview, a urogynaecological examination, in addition to the Urinary Symptoms Profile (USP) [10] and the International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) questionnaires [11] (from 2011 to 2017). Neurogenic SUI was defined as SUI in a patient with spinal cord injury or spina bifida.
Follow-up involved an outpatient visit at 3 months, 6 months, and 1 year postoperatively and then annually with a clinical examination, a 3-day bladder diary and uroflowmetry with ultrasound measurement of the post-void residual urine volume. Urodynamic testing was performed 3 months after AUS implantation to measure postoperative urethral closure pressure, but was not performed routinely after ACT® implantation (only in the case of persistent urinary incontinence after inflation of up to 5 ml per balloon).
Postoperative complications were graded using the Clavien-Dindo classification [12] and were reported according to the EAU guidelines [13] . Failure was defined as explantation of the AUS device and divided into two categories: mechanical failure (perforation of any parts of the AUS or pump malfunction) and nonmechanical failure (cuff erosion, infection, pain, insufficient pressure). Hence, failure and continence status were analyzed separately and failure defined only the impossibility of maintaining the device in situ. Acute urinary retention was defined as a post-void residual volume > 150 ml postoperatively, spontaneously resolving within the first 3 months after surgery. Chronic urinary retention was defined as the persistence of a post-void residual volume > 150 ml more than 3 months after the implantation. All urinary retentions were managed by clean-intermittent self-catheterizations (4-6 per day).
Statistical analysis
Perioperative and functional parameters were compared between the two groups. Means and standard deviations were reported for continuous variables, and proportions for nominal variables. Comparisons between groups were performed using the χ 2 test or Fisher's exact test for discrete variables, and Mann-Whitney test for continuous variables. Change of continuous variables over time was assessed using the McNemar test. Time to failure was estimated using the Kaplan-Meier method and compared in the two groups using the log-rank test. Statistical analyses were performed using JMP v.12.0 software (SAS Institute, Cary, NC, USA). All tests were two-sided with a level of p < 0.05 considered statistically significant.
Results
Patients' characteristics
Over the study period, 61 patients were screened and all met the inclusion criteria: 25 underwent an ACT® implantation and 36 an AUS implantation. The study flow-chart is shown in Fig. 1 . The patients' characteristics are summarized in Table 1 . Patients in the AUS group were younger (62.9 vs 70.4 years; p = 0.03) with less comorbidity (ASA score = 3 in 12.1% vs 33.3%; p = 0.005) and none had a history of previous pelvic radiation therapy; conversely, those in the ACT® group did (0% vs 20%; p = 0.009). A previous midurethral sling failed in more patients undergoing an AUS implantation (66.7% vs 40%; p = 0.04), but the rate of neurogenic SUI was comparable in the two groups (13.9% vs 4%; p = 0.39) and the maximum urethral closure pressure did not differ significantly between the AUS and ACT® groups (27.3 vs 28.8 cm H 2 O; p = 0.61). The proportion of patients who had undergone a second midurethral sling was also similar in the two groups (27.8% vs 13.6%; p = 0.21). The reasons for ACT® implantations were as follows: moderate incontinence in 5 patients (20%), comorbidities in 10 patients (40%), and 10 patients were offered an AUS but refused and then underwent implantation of ACT® (40%). Eight and 5 patients in the ACT and AUS group respectively had not undergone any anti-incontinence surgical procedure (32% vs 13.9%; p = 0.12).
Perioperative outcomes
The perioperative outcomes are shown in Table 2 ; p = 0.28) did not differ significantly in the two groups. There were 2 Clavien-Dindo 3a complications in the ACT® group, which were early vaginal erosions associated with a device infection that required explantation under local anesthesia in both cases. In the AUS group, 7 Clavien-Dindo 3b complications occurred; 5 device infections and 2 large erosions that all required an explantation of the AUS under general anesthesia. The last major complication in the AUS group was a device infection, which occurred after a change of a first sphincter that became infected and was treated conservatively. It was almost always associated with a bladder neck injury during the procedure. No Clavien-Dindo 4 or 5 complications occurred in either of the groups. After a mean follow-up of 44.3 months in the AUS group (vs 22.3 months in the ACT® group; p = 0.02), the explantation rates were similar in the two groups (19.4% vs 20%; p = 0.99). All 5 explantations in the ACT® group were due to nonmechanical failure: device infection in 2 cases, symptoms worsening in 2 cases, and in 1 case, the ACT® was explanted before implantation of an AUS. Explantations in the AUS group were due to nonmechanical failure: 5 were due to device infections; 1 to large vaginal erosion, and 1 was explanted because of a bladder neck erosion. When a mechanical failure occurred, we managed the situation with a surgical revision and it has always been done successfully. Time-tofailure is shown in Fig. 2 (12-month cumulative failure rate: 14% in the AUS group vs 22% in the ACT® group; p = 0.42).
Functional outcomes
The mean number of inflations in the ACT® group was 2.9 per balloon and the mean final volume of each balloon was 3.4 ml. In the AUS group a 61-to 70-cm H 2 O pressure balloon was used in all except 1 case (71-80 cm H 2 O) and the median cuff size was 70 mm. The decrease in USP stress incontinence subscore was significantly greater in the AUS group (−7.6 vs −3.2; p < 0.001; Supplementary Fig. 1 ) and so was the decrease in mean number of pads per 24 h (−4.6 vs −2.3; p = 0.002; Table 3 ). The Patient Global Impression of Improvement (PGII) [14] was better in the AUS group (PGII = 1: 61.1% vs 12%; p < 0.001) as was the rate of patients cured (71.4% vs 21.7%; p < 0.001). Five patients in the ACT® group required the use of clean-intermittent self-catheterization postoperatively, at least for some time, compared with only 1 in the AUS group (20% vs 2.8%; p = 0.04). Two of the 5 patients who experienced urinary retention in the ACT® group complained of this condition; thus, their balloons were partly deflated and both recovered spontaneous voiding.
Subgroup of persistent/recurrent stress urinary incontinence after midurethral slings
In this subgroup, none of the patients in the ACT® group had undergone previous pelvic radiation therapy. Mean age was similar in the two groups (71.7 vs 66.4; p = 0.23; Table 4 ) and the maximum urethral closure pressure values of patients who underwent an AUS or an ACT® implantation were comparable (24.9 vs 26.4 cm H2O; p = 0.64). The proportion of patients who had undergone a second midurethral sling in the two groups did not differ significantly (37.5% vs 10%; p = 0.21). The rate of intraoperative complications remained higher in the AUS group (54.2% vs 10%; p = 0.02). The rate of postoperative complications tended to be higher in the AUS group (54.2% vs 20%; p = 0.13). The explantation rates of the two groups did not differ significantly (30% vs 25%; p = 0.99). AUS outperformed ACT® in terms of functional outcomes, with a higher cure rate (66.7% vs 30%; p = 0.04) and a greater decrease in USP stress incontinence subscore (−8 vs -5.3; p = 0.003). 
Discussion
According to the International Consultation on Urological Diseases (ICUD), SUI affects from 5-15% and up to 30% in women over 70 years of age [15] . Two decades ago, the works of Ulmsten and DeLancey changed the understanding of SUI by outlining the distinct role of urethral support and the function of the urethral muscles [16, 17] . This gave birth to the concept of intrinsic sphincter deficiency meaning impaired sphincter functioning due to the loss of elasticity and coaptation [18] . Although most SUI in female patients is mainly due to urethral hypermobility, the exact proportion of these women who suffer from some degree of intrinsic sphincter deficiency remains unknown [1] . The optimal management of women with SUI due to intrinsic sphincter deficiency is still a matter of debate. The American Urological Association (AUA) 2017 guidelines [19] do not mention the role of AUS or ACT® in their treatment algorithm; the European Association of Urology (EAU) 2017 guidelines consider that they might play a role, but that a secondary synthetic sling, colposuspension or an autologous sling is the first option for women with complicated SUI [20] . The French Association of Urology (AFU) recommends AUS as the gold-standard treatment for severe SUI due to intrinsic sphincter deficiency and ACT® as a possible alternative in these patients [21] . These heterogeneous recommendations may be explained by the paucity of data in the literature. To date, no study has compared fascial slings with AUS or ACT®. To our knowledge, the present series is one of the first to compare two different techniques of intrinsic sphincter deficiency management in female patients and the first to compare these two specific devices. In the present study, AUS implantation was associated with better functional outcomes than ACT® implantation in female patients with SUI due to intrinsic sphincter deficiency, but with a higher intraoperative complications rate, longer operative time, and prolonged length of stay. The morbidity of AUS implantation was higher than that of ACT®, despite comparable a postoperative complications rate. The high morbidity of the AUS in female patients has often been assumed to be the key factor that has limited its widespread use [4] . This high complication rate may be due to the technically challenging dissection of the bladder neck, located deep in the pelvis, with an urethral-vaginal septum that is often difficult to open because of the amount of previous surgical procedures. In recent years, the use of a robotic approach has been proposed to facilitate AUS implantation in women [22] . In a preliminary report, robotic AUS implantation appeared to decrease the postoperative complications rate, blood loss, and length of stay, with a trend toward lower intraoperative complications compared with the open approach. Hence, it may be assumed that the difference we observed in terms of morbidity between AUS and ACT® may be tempered with a purely robotic AUS cohort (our cohort included a mix of open, laparoscopic, and robotic AUS implantation).
It is now widely accepted through the urogynecology community that rather than looking for an objective cure in every case, physicians should adapt their treatments to the patient's expectations and profile [23] . Our results are of interest in that regard, as AUS, by outperforming ACT® in terms of functional outcomes, may be an appropriate option for patients with intrinsic sphincter deficiency seeking a cure for their urinary incontinence. Conversely, with its fair safety profile, despite older patients with more comorbidity and previous pelvic radiation therapy (20%), the ACT® could be a reliable option for patients looking for improvement of their urinary incontinence.
Another point of interest of this study is that the ACT® was associated with an increased risk of urinary retention postoperatively. This finding emphasizes an important point of strength of the AUS, in that it is the only therapy for SUI due to intrinsic sphincter deficiency, increasing urethral pressure during storage, while maintaining a low urethral resistance during voiding by opening the device cuff. Indeed, the mechanism of action of ACT® is similar to that of other treatment options, such as fascial slings or bulking agents, by creating a permanent (i.e., that cannot be relieved) external compression over the urethra to preserve continence [5] . Long-term data regarding the impact of this increased bladder outlet resistance on detrusor contractility are lacking [24] , but by analogy with what is seen in men with long-lasting benign prostate obstruction, it could be assumed that these external compression treatment options (i.e., ACT®, bulking agent or fascial sling) may lead to detrusor underactivity in the long term. The benefits of ACT over bulking agents or fascial slings in that regard is that the obstruction can be fully relieved, as outlined in our series, by deflating the balloons. Our study had several limitations that should be emphasized. First, its retrospective and nonrandomized design could have partly skewed our results, notably because of an obvious selection bias, with patients' characteristics differing in the two groups, which we aimed to balance out by performing a subgroup analysis. Another limitation is the relatively small sample size of our series, which may lead to a lack of statistical power and which prevented us from performing multivariate analyses. We reported the early experience of a medium volume center for the two techniques and our findings may have differed if coming from a tertiary volume center with a larger experience in AUS and ACT® implantations. There is still no consensus regarding the definition of intrinsic sphincter deficiency and the one we used in this study could therefore be a matter of debate. The various approaches used in the AUS group (i.e., open, laparoscopic, robot-assisted) may have been a confounder when analyzing perioperative outcomes. Despite these drawbacks, we believe that the comparative data we provide are of value, whereas the optimal management of SUI due to intrinsic sphincter deficiency remains to be determined.
Conclusion
In the present series, the patients in the two groups differed significantly in age, ASA score, history of pelvic radiation therapy, and history of previous midurethral sling, which may have biased our findings. AUS implantation was associated with better functional outcomes than the ACT® in female patients with SUI due to intrinsic sphincter deficiency, but with a higher intraoperative complications rate, longer operative time, and longer stay. Postoperative complications and explantation rates were similar in the two groups. Future prospective randomized trials are needed to better define treatment algorithms of female patients with SUI due to intrinsic sphincter deficiency.
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